| 发明名称 |
Protein arginine N-methyltransferase-5 method of cancer treatment |
| 摘要 |
A method for the treatment of a proliferative disease comprising providing a E2F-1 protein which is arginine-methylation defective or administering a substance which reduces the expression and/or activity of PRMT5. The invention also provides antibodies, screening methods and kits. |
| 申请公布号 |
US8841274(B2) |
申请公布日期 |
2014.09.23 |
| 申请号 |
US201013518200 |
申请日期 |
2010.12.20 |
| 申请人 |
|
发明人 |
Lathangue Nicholas |
| 分类号 |
C12N15/11;C07K14/47;C12N15/113;C07K16/18;C07K16/44;G01N33/574 |
主分类号 |
C12N15/11 |
| 代理机构 |
Rothwell, Figg, Ernst & Manbeck P.C. |
代理人 |
Rothwell, Figg, Ernst & Manbeck P.C. |
| 主权项 |
1. A method for the treatment of a cancer in an individual wherein said cancer expresses protein arginine N-methyl-transferase 5 (PRMT5) and has increased methylation of the E2F-1 protein compared to noncancerous tissue comprising administering a therapeutically effective amount of an antisense molecule, an shRNA, an siRNA or a small molecule inhibitor of PRMT5to an individual in need thereof, wherein said antisense molecule, said shRNA, said siRNA or said small molecule reduces expression or activity of said PRMT5 in said cancer thereby reducing or abolishing the ability of said PRMT5 to methylate said E2F-1 protein thereby promoting E2F-1-dependent apoptosis. |
| 地址 |
|
